Alembic Pharmaceuticals announces USFDA Final Approval for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg.

Naman Bansal July 24, 2024 PR

24th July 2024, Bengaluru: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Prolixin Tablets, 1 mg, 2.5 mg, 5mg, and 10 mg, of Apothecon Inc. (Apothecon). Fluphenazine hydrochloride tablets, USP are indicated in the management of manifestations of psychotic disorders. Refer label for a detailed indication.

Alembic has a cumulative total of 210 ANDA approvals (182 final approvals and 28 tentative approvals) from USFDA.

Check Also

Motorola Announces Special Limited-Period Offers on moto g37 and moto g37 POWER; The Best Value 5G Smartphones Now Available Starting at Just ₹13,999 Available at Flipkart, moto.in and leading retail stores.

For a limited period, consumers can get Motorola’s most power-packed smartphone under ₹20,000 moto g37 POWER at an effective …

Copyright © 2025, NewsPatrolling.com

toto slot